HealthEquity stock hits 52-week high at $101.34 amid robust growth

HealthEquity Inc (HQY) stock soared to a 52-week high of $101.34, marking a significant milestone for the health savings account provider. This peak reflects a substantial 49.81% increase in the stock's value over the past year, underscoring the company's strong performance and investor confidence. The impressive one-year change in HealthEquity's stock price highlights the company's successful strategies and robust market position, as it continues to capitalize on the growing demand for health savings solutions.

In other recent news, HealthEquity has been the focus of several analyst reports. Goldman Sachs initiated coverage on HealthEquity, assigning a Neutral rating with a price target of $108.00. The firm's analysis suggests a balanced perspective on the company's potential for earnings growth, tempered by the current stock valuation. Meanwhile, RBC Capital Markets increased its price target for HealthEquity to $100, maintaining an Outperform rating. KeyBanc also maintained its Overweight rating on the company, with a steady price target of $100.00.

In their recent earnings call, HealthEquity reported a 23% increase in revenue, a 46% rise in adjusted EBITDA, and a 27% growth in Health Savings Accounts (HSAs) assets. The company successfully completed the final part of the BenefitWallet acquisition, adding 216,000 HSAs and $1.0 billion in assets. HealthEquity also introduced Health Payment Accounts (HPAs) and announced a new $300 million share repurchase program.

For fiscal 2025, HealthEquity expects revenue to range from $1.165 billion to $1.185 billion, and adjusted EBITDA to fall between $458 million and $478 million. These recent developments highlight HealthEquity's dedication to growth and innovation.

InvestingPro Insights

HealthEquity's recent stock performance aligns with several key metrics and insights from InvestingPro. The company's market capitalization stands at $8.77 billion, reflecting its significant presence in the health savings account sector. InvestingPro data shows that HealthEquity has experienced robust revenue growth, with a 17.19% increase over the last twelve months and an even more impressive 23.15% growth in the most recent quarter.

Two particularly relevant InvestingPro Tips highlight the company's current position:

1. HealthEquity is trading near its 52-week high, which corroborates the article's mention of the stock reaching $101.34.

2. The company has shown a strong return over the last three months, with InvestingPro data indicating a 32.18% price total return over this period.

These insights reinforce the article's narrative of HealthEquity's strong performance and investor confidence. For readers seeking a deeper understanding of HealthEquity's financial health and market position, InvestingPro offers 12 additional tips, providing a comprehensive analysis of the company's prospects and valuation metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.